Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?

被引：0
|
作者：
Lucien Marchand
Sophie Reffet
Stéphane Dalle
Emmanuel Disse
Julien Vouillarmet
Christine Cugnet-Anceau
Charles Thivolet
机构：
[1] Hospices Civils de Lyon,Department of Endocrinology and Diabetes
[2] Lyon-Sud Hospital,Department of Dermatology
[3] Hospices Civils de Lyon,ImmuCare (Immunology Cancer Research)
[4] Lyon-Sud Hospital,undefined
[5] Hospices Civils de Lyon,undefined
[6] Lyon 1 University,undefined
[7] CarMeN Laboratory (INSERM U1060,undefined
[8] INRA U1235,undefined
[9] Université Claude Bernard Lyon1,undefined
[10] INSA-Lyon),undefined
来源：
Acta Diabetologica | 2019年 / 56卷
关键词：
Diabetes mellitus; Fulminant diabetes; Glucose variability; Coefficient of variation for glucose; Labile diabetes; Flash glucose monitoring; FreeStyle Libre; Autoimmune diabetes; Immune checkpoint inhibitors side effects; Immunotherapy; Programmed cell death-1; Anti-PD-1; Programmed death ligand 1; Anti-PD-L1; Beta-cell pancreatic function; Alpha-cell pancreatic function; Exocrine pancreatic function;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：377 / 378
页数：1
相关论文
共 50 条
  • [41] PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
    Zhang, Ke
    Kong, Xiangyi
    Li, Yuan
    Wang, Zhongzhao
    Zhang, Lin
    Xuan, Lixue
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [42] Photodynamic Therapy enhances the Effect of PD-1/PD-L1 Inhibitors
    Erhard, Daniela
    AKTUELLE DERMATOLOGIE, 2019, 45 (07) : 316 - 316
  • [43] Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
    Anand, Kartik
    Sahu, Geetanjali
    Burns, Ethan
    Ensor, Allyne
    Ensor, Joe
    Pingali, Sai Ravi
    Subbiah, Vivek
    Iyer, Swaminathan P.
    ESMO OPEN, 2020, 5 (04)
  • [44] Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
    Cheng, Chao
    Zhuge, Lingdun
    Xiao, Xin
    Luan, Siyuan
    Yuan, Yong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [45] Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
    Shen, Xian
    Zhao, Bin
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
  • [46] Modifications of the miniprotein sequences for enhanced affinity to PD-1: tailoring inhibitors of the PD-1/PD-L1 interaction
    Nocen, Pawel
    Berlicki, Lukasz
    JOURNAL OF PEPTIDE SCIENCE, 2024, 30
  • [47] New advances in the study of PD-1/PD-L1 inhibitors-induced liver injury
    Yue, Meijun
    Li, Chunyu
    Li, Guohui
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 131
  • [48] Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer
    Wang, Yanling
    Yang, Xiaoxuan
    Ma, Jia
    Chen, Shenglan
    Gong, Ping
    Dai, Ping
    HELIYON, 2024, 10 (05)
  • [49] PD-1 and PD-L1 prognostic in UTUC
    Stone, Louise
    NATURE REVIEWS UROLOGY, 2017, 14 (09) : 518 - 518
  • [50] PD-1 and PD-L1 prognostic in UTUC
    Louise Stone
    Nature Reviews Urology, 2017, 14 : 518 - 518
12345